Related Experiment Video

Updated: Jun 19, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Cyclin-Dependent Kinases 4 and 6 Inhibitors: An Emerging Therapeutic Framework from Growth Suppression to Tumor

Cong Ma1, Xuan Ji1, Wenqin Huang1

  • 1Breast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, China.

ACS Pharmacology & Translational Science
|June 18, 2026
PubMed

Insights

Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors can be combined with other therapies to overcome resistance and improve tumor clearance. This approach shifts treatment from growth suppression to tumor eradication for better outcomes.

Area of Science:

  • Oncology
  • Cancer Therapeutics
  • Molecular Biology

Background:

  • Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are crucial in cancer therapy but face limitations like reversible cytostasis and acquired resistance.
  • Understanding the mechanisms behind these limitations is key to developing more effective treatment strategies.

Purpose of the Study:

  • To explore strategies for overcoming clinical limitations of CDK4/6 inhibitors.
  • To present a therapeutic framework that leverages CDK4/6 inhibitor-induced vulnerabilities for tumor clearance.
  • To summarize rational combination strategies to enhance CDK4/6 inhibitor efficacy.

Main Methods:

  • Review of preclinical and clinical data on CDK4/6 inhibitors.
  • Analysis of CDK4/6 inhibitor effects on cellular senescence, DNA damage repair, metabolism, and the immune microenvironment.
  • Synthesis of evidence supporting combination therapies.

Main Results:

  • CDK4/6 inhibitors induce vulnerabilities in cellular senescence, DNA damage repair, metabolic reprogramming, and immune microenvironment.
  • Combination strategies, including senolytics, PARP inhibitors, and immune checkpoint inhibitors (ICIs), can exploit these vulnerabilities.
  • Biomarker-guided patient selection and optimized dosing schedules are critical for clinical success.

Conclusions:

  • Rational combination strategies can repurpose CDK4/6 inhibitors for more durable tumor control.
  • Exploiting induced vulnerabilities offers a path beyond simple growth suppression.
  • Translational determinants are essential for successful clinical implementation of combination therapies.
Keywords:
CDK4/6 inhibitorsDNA damage repaircellular senescencecombination therapyimmune microenvironment remodelingmetabolic reprogramming

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.